Search

Your search keyword '"Watanabe, Hirotoshi"' showing total 213 results
Start Over Author "Watanabe, Hirotoshi" Search Limiters Full Text
213 results on '"Watanabe, Hirotoshi"'

1. Single-Session Versus Staged Multivessel Optimal IVUS-Guided PCI in Patients With CCS or NSTE-ACS

Author

Yamamoto, Ko, Shiomi, Hiroki, Morimoto, Takeshi, Miyazawa, Akiyoshi, Watanabe, Hiroki, Nakamura, Sunao, Suwa, Satoru, Domei, Takenori, Ono, Koh, Sakamoto, Hiroki, Shigetoshi, Masataka, Taniguchi, Ryoji, Okayama, Hideki, Toyota, Toshiaki, Yokomatsu, Takafumi, Muto, Masahiro, Kawaguchi, Ren, Kishi, Koichi, Hadase, Mitsuyoshi, Fujita, Tsutomu, Nishida, Yasunori, Nishino, Masami, Otake, Hiromasa, Natsuaki, Masahiro, Watanabe, Hirotoshi, Suematsu, Nobuhiro, Tanabe, Kengo, Abe, Mitsuru, Hibi, Kiyoshi, Kadota, Kazushige, Ando, Kenji, and Kimura, Takeshi

Published
2023
Full Text
View/download PDF

2. Clopidogrel Monotherapy After 1-Month DAPT in Patients With High Bleeding Risk or Complex PCI

Author

Yamamoto, Ko, Watanabe, Hirotoshi, Morimoto, Takeshi, Obayashi, Yuki, Natsuaki, Masahiro, Domei, Takenori, Yamaji, Kyohei, Suwa, Satoru, Isawa, Tsuyoshi, Watanabe, Hiroki, Yoshida, Ruka, Sakamoto, Hiroki, Akao, Masaharu, Hata, Yoshiki, Morishima, Itsuro, Tokuyama, Hideo, Yagi, Masahiro, Suzuki, Hiroshi, Wakabayashi, Kohei, Suematsu, Nobuhiro, Inada, Tsukasa, Tamura, Toshihiro, Okayama, Hideki, Abe, Mitsuru, Kawai, Kazuya, Nakao, Koichi, Ando, Kenji, Tanabe, Kengo, Ikari, Yuji, Morino, Yoshihiro, Kadota, Kazushige, Furukawa, Yutaka, Nakagawa, Yoshihisa, and Kimura, Takeshi

Published
2023
Full Text
View/download PDF

3. Defining Strategies of Modulation of Antiplatelet Therapy in Patients With Coronary Artery Disease: A Consensus Document from the Academic Research Consortium

Author

Capodanno, Davide, Mehran, Roxana, Krucoff, Mitchell W., Baber, Usman, Bhatt, Deepak L., Capranzano, Piera, Collet, Jean-Philippe, Cuisset, Thomas, De Luca, Giuseppe, De Luca, Leonardo, Farb, Andrew, Franchi, Francesco, Gibson, C. Michael, Hahn, Joo-Yong, Hong, Myeong-Ki, James, Stefan, Kastrati, Adnan, Kimura, Takeshi, Lemos, Pedro A., Lopes, Renato D., Magee, Adrian, Matsumura, Ryosuke, Mochizuki, Shuichi, O’Donoghue, Michelle L., Pereira, Naveen L., Rao, Sunil V., Rollini, Fabiana, Shirai, Yuko, Sibbing, Dirk, Smits, Peter C., Steg, P. Gabriel, Storey, Robert F., ten Berg, Jurrien, Valgimigli, Marco, Vranckx, Pascal, Watanabe, Hirotoshi, Windecker, Stephan, Serruys, Patrick W., Yeh, Robert W., Morice, Marie-Claude, and Angiolillo, Dominick J.

Published
2023
Full Text
View/download PDF

4. Target Lesion Revascularization After Intravascular Ultrasound-Guided Percutaneous Coronary Intervention

Author

Yamamoto, Ko, Shiomi, Hiroki, Morimoto, Takeshi, Miyazawa, Akiyoshi, Watanabe, Hiroki, Natsuaki, Masahiro, Watanabe, Hirotoshi, Yamaji, Kyohei, Ohya, Masanobu, Nakamura, Sunao, Mitomo, Satoru, Suwa, Satoru, Domei, Takenori, Tatsushima, Shojiro, Ono, Koh, Sakamoto, Hiroki, Shimamura, Kiyotaka, Shigetoshi, Masataka, Taniguchi, Ryoji, Nishimoto, Yuji, Okayama, Hideki, Matsuda, Kensho, Yokomatsu, Takafumi, Muto, Masahiro, Kawaguchi, Ren, Kishi, Koichi, Hadase, Mitsuyoshi, Fujita, Tsutomu, Nishida, Yasunori, Nishino, Masami, Otake, Hiromasa, Suematsu, Nobuhiro, Ajimi, Tsuneki, Tanabe, Kengo, Abe, Mitsuru, Hibi, Kiyoshi, Kadota, Kazushige, Ando, Kenji, and Kimura, Takeshi

Published
2023
Full Text
View/download PDF

6. Stent-Related Adverse Events as Related to Dual Antiplatelet Therapy in First- vs Second-Generation Drug-Eluting Stents

Author

Yoshikawa, Yusuke, Shiomi, Hiroki, Morimoto, Takeshi, Takeji, Yasuaki, Matsumura-Nakano, Yukiko, Yamamoto, Ko, Yamamoto, Erika, Kato, Eri T., Watanabe, Hirotoshi, Saito, Naritatsu, Domei, Takenori, Tada, Takeshi, Nawada, Ryuzo, Onodera, Tomoya, Suwa, Satoru, Tamura, Toshihiro, Ishii, Katsuhisa, Ando, Kenji, Furukawa, Yutaka, Kadota, Kazushige, Nakagawa, Yoshihisa, and Kimura, Takeshi

Published
2021
Full Text
View/download PDF

8. Preferred monotherapy after short-term dual antiplatelet therapy: Systematic review and network Meta-analysis of randomized trials

Author

Shoji, Satoshi, primary, Kuno, Toshiki, additional, Ueyama, Hiroki, additional, Takagi, Hisato, additional, Briasoulis, Alexandros, additional, Kim, Hyo-Soo, additional, Koo, Bon-Kwon, additional, Kang, Jeehoon, additional, Watanabe, Hirotoshi, additional, Kimura, Takeshi, additional, and Kohsaka, Shun, additional

Published
2023
Full Text
View/download PDF

9. Prognostic Impact of Left Ventricular Ejection Fraction in Patients With Severe Aortic Stenosis

Author

Kimura, Takeshi, Taniguchi, Tomohiko, Shiomi, Hiroki, Saito, Naritatsu, Imai, Masao, Tazaki, Junichi, Toyota, Toshiaki, Higami, Hirooki, Kawaji, Tetsuma, Ando, Kenji, Shirai, Shinichi, Kourai, Kengo, Arita, Takeshi, Miura, Shiro, Yamaji, Kyohei, Aoyama, Takeshi, Kanamori, Norio, Onodera, Tomoya, Murata, Koichiro, Furukawa, Yutaka, Kitai, Takeshi, Kim, Kitae, Kadota, Kazushige, Kawase, Yuichi, Iwasaki, Keiichiro, Miyawaki, Hiroshi, Misao, Ayumi, Kuwayama, Akimune, Ohya, Masanobu, Shimada, Takenobu, Amano, Hidewo, Nakagawa, Yoshihisa, Izumi, Chisato, Miyake, Makoto, Amano, Masashi, Takahashi, Yusuke, Yoshikawa, Yusuke, Nishimura, Shunsuke, Kuroda, Maiko, Shirotani, Manabu, Mitsuoka, Hirokazu, Miki, Shinji, Mizoguchi, Tetsu, Kato, Masashi, Yokomatsu, Takafumi, Kushiyama, Akihiro, Yaku, Hidenori, Watanabe, Toshimitsu, Miyazaki, Shunichi, Hirano, Yutaka, Matsuda, Mitsuo, Matsuda, Shintaro, Sugioka, Sachiko, Inada, Tsukasa, Nagao, Kazuya, Takahashi, Naoki, Fukuchi, Kohei, Murakami, Tomoyuki, Mabuchi, Hiroshi, Takeda, Teruki, Sakaguchi, Tomoko, Maeda, Keiko, Yamaji, Masayuki, Maenaka, Motoyoshi, Tadano, Yutaka, Sakamoto, Hiroki, Takeuchi, Yasuyo, Motooka, Makoto, Nishikawa, Ryusuke, Eizawa, Hiroshi, Yamane, Keiichiro, Kawato, Mitsunori, Kinoshita, Minako, Aida, Kenji, Tamura, Takashi, Toyofuku, Mamoru, Takahashi, Kousuke, Ko, Euihong, Akao, Masaharu, Ishii, Mitsuru, Masunaga, Nobutoyo, Ogawa, Hisashi, Iguchi, Moritake, Unoki, Takashi, Takabayashi, Kensuke, Hamatani, Yasuhiro, Yamashita, Yugo, Inoko, Moriaki, Minamino-Muta, Eri, Kato, Takao, Himura, Yoshihiro, Ikeda, Tomoyuki, Ishii, Katsuhisa, Komasa, Akihiro, Sato, Yukihito, Hotta, Kozo, Tsuji, Shuhei, Hiraoka, Yuji, Higashitani, Nobuya, Kouchi, Ichiro, Kato, Yoshihiro, Ikeguchi, Shigeru, Inuzuka, Yasutaka, Nishio, Soji, Seki, Jyunya, Shinoda, Eiji, Yamada, Miho, Kawamoto, Akira, Maeda, Chiyo, Konishi, Takashi, Jinnai, Toshikazu, Sogabe, Kouji, Tachiiri, Michiya, Matsumura, Yukiko, Ota, Chihiro, Kitaguchi, Shoji, Morikami, Yuko, Sakata, Ryuzo, Minakata, Kenji, Minatoya, Kenji, Hanyu, Michiya, Yamazaki, Fumio, Koyama, Tadaaki, Komiya, Tatsuhiko, Yamanaka, Kazuo, Nishiwaki, Noboru, Nakajima, Hiroyuki, Ohnaka, Motoaki, Osada, Hiroaki, Meshii, Katsuaki, Saga, Toshihiko, Onoe, Masahiko, Nakayama, Shogo, Sakaguchi, Genichi, Iwakura, Atsushi, Shiraga, Kotaro, Ueyama, Koji, Fujiwara, Keiichi, Fukumoto, Atsushi, Park, Masaki, Nishizawa, Junichiro, Kitano, Mitsuru, Morimoto, Takeshi, Nakatsuma, Kenji, Sasa, Tomoki, Watanabe, Hirotoshi, Kuwabara, Yasuhide, Makiyama, Takeru, Ono, Koh, and Shizuta, Satoshi

Published
2018
Full Text
View/download PDF

10. Very Short Dual Antiplatelet Therapy After Drug-Eluting Stent Implantation in Patients With High Bleeding Risk: Insight From the STOPDAPT-2 Trial

Author

Watanabe, Hirotoshi, Domei, Takenori, Morimoto, Takeshi, Natsuaki, Masahiro, Shiomi, Hiroki, Toyota, Toshiaki, Ohya, Masanobu, Suwa, Satoru, Takagi, Kensuke, Nanasato, Mamoru, Hata, Yoshiki, Yagi, Masahiro, Suematsu, Nobuhiro, Yokomatsu, Takafumi, Takamisawa, Itaru, Doi, Masayuki, Noda, Toshiyuki, Okayama, Hideki, Seino, Yoshitane, Tada, Tomohisa, Sakamoto, Hiroki, Hibi, Kiyoshi, Abe, Mitsuru, Kawai, Kazuya, Nakao, Koichi, Ando, Kenji, Tanabe, Kengo, Ikari, Yuji, Hanaoka, Keiichi Igarashi, Morino, Yoshihiro, Kozuma, Ken, Kadota, Kazushige, Furukawa, Yutaka, Nakagawa, Yoshihisa, and Kimura, Takeshi

Published
2019
Full Text
View/download PDF

12. TEN-YEAR OUTCOME OF A TRIAL COMPARING SECOND GENERATION DRUG-ELUTING STENTS USING EITHER BIODEGRADABLE POLYMER OR DURABLE POLYMER

Author

Natsuaki, Masahiro, primary, Morimoto, Takeshi, additional, Watanabe, Hirotoshi, additional, Kozuma, Ken, additional, Kadota, Kazushige, additional, Nakagawa, Yoshihisa, additional, Akasaka, Takashi, additional, Igarashi, Keiichi, additional, Tanabe, Kengo, additional, Morino, Yoshihiro, additional, and Kimura, Takeshi, additional

Published
2023
Full Text
View/download PDF

13. P2Y12 Inhibitor Monotherapy or Dual Antiplatelet Therapy After Complex Percutaneous Coronary Interventions

Author

Gragnano, Felice, primary, Mehran, Roxana, additional, Branca, Mattia, additional, Franzone, Anna, additional, Baber, Usman, additional, Jang, Yangsoo, additional, Kimura, Takeshi, additional, Hahn, Joo-Yong, additional, Zhao, Qiang, additional, Windecker, Stephan, additional, Gibson, Charles M., additional, Kim, Byeong-Keuk, additional, Watanabe, Hirotoshi, additional, Song, Young Bin, additional, Zhu, Yunpeng, additional, Vranckx, Pascal, additional, Mehta, Shamir, additional, Hong, Sung-Jin, additional, Ando, Kenji, additional, Gwon, Hyeon-Cheol, additional, Calabrò, Paolo, additional, Serruys, Patrick W., additional, Dangas, George D., additional, McFadden, Eùgene P., additional, Angiolillo, Dominick J., additional, Heg, Dik, additional, and Valgimigli, Marco, additional

Published
2023
Full Text
View/download PDF

14. Low-Density Lipoprotein Cholesterol Levels on Statins and Cardiovascular Event Risk in Stable Coronary Artery Disease ― An Observation From the REAL-CAD Study ―

Author

Toyota, Toshiaki, primary, Morimoto, Takeshi, additional, Iimuro, Satoshi, additional, Fujita, Retsu, additional, Iwata, Hiroshi, additional, Miyauchi, Katsumi, additional, Inoue, Teruo, additional, Nakagawa, Yoshihisa, additional, Nishihata, Yosuke, additional, Daida, Hiroyuki, additional, Ozaki, Yukio, additional, Suwa, Satoru, additional, Sakuma, Ichiro, additional, Furukawa, Yutaka, additional, Shiomi, Hiroki, additional, Watanabe, Hirotoshi, additional, Yamaji, Kyohei, additional, Saito, Naritatsu, additional, Natsuaki, Masahiro, additional, Ohashi, Yasuo, additional, Matsuzaki, Masunori, additional, Nagai, Ryozo, additional, and Kimura, Takeshi, additional

Published
2023
Full Text
View/download PDF

15. Clopidogrel Monotherapy After 1-Month Dual Antiplatelet Therapy in Patients With Diabetes Undergoing Percutaneous Coronary Intervention

Author

Yamamoto, Ko, primary, Watanabe, Hirotoshi, additional, Morimoto, Takeshi, additional, Obayashi, Yuki, additional, Natsuaki, Masahiro, additional, Yamaji, Kyohei, additional, Domei, Takenori, additional, Ogita, Manabu, additional, Ohya, Masanobu, additional, Tatsushima, Shojiro, additional, Suzuki, Hirohiko, additional, Tada, Tomohisa, additional, Ishii, Mitsuru, additional, Nikaido, Akira, additional, Watanabe, Naoki, additional, Fujii, Shinya, additional, Mori, Hiroyoshi, additional, Nishikura, Tenjin, additional, Suematsu, Nobuhiro, additional, Hayashi, Fujio, additional, Komiyama, Kota, additional, Shigematsu, Tatsuya, additional, Isawa, Tsuyoshi, additional, Suwa, Satoru, additional, Ando, Kenji, additional, and Kimura, Takeshi, additional

Published
2023
Full Text
View/download PDF

16. Optimal Cutoff Value of Fractional Flow Reserve Derived From Coronary Computed Tomography Angiography for Predicting Hemodynamically Significant Coronary Artery Disease

Author

Matsumura-Nakano, Yukiko, Kawaji, Tetsuma, Shiomi, Hiroki, Kawai-Miyake, Kanae, Kataoka, Masako, Koizumi, Koji, Matsuda, Akira, Kitano, Kazuki, Yoshida, Masaharu, Watanabe, Hirotoshi, Tazaki, Junichi, Kato, Takao, Saito, Naritatsu, Shizuta, Satoshi, Ono, Koh, Togashi, Kaori, Morimoto, Takeshi, and Kimura, Takeshi

Published
2019
Full Text
View/download PDF

19. Dual antiplatelet therapy duration after percutaneous coronary intervention in high bleeding risk: a meta-analysis of randomized trials

Author

Costa, Francesco, primary, Montalto, Claudio, additional, Branca, Mattia, additional, Hong, Sung-Jin, additional, Watanabe, Hirotoshi, additional, Franzone, Anna, additional, Vranckx, Pascal, additional, Hahn, Joo-Yong, additional, Gwon, Hyeon-Cheol, additional, Feres, Fausto, additional, Jang, Yangsoo, additional, De Luca, Giuseppe, additional, Kedhi, Elvin, additional, Cao, Davide, additional, Steg, Philippe Gabriel, additional, Bhatt, Deepak L, additional, Stone, Gregg W, additional, Micari, Antonio, additional, Windecker, Stephan, additional, Kimura, Takeshi, additional, Hong, Myeong-Ki, additional, Mehran, Roxana, additional, and Valgimigli, Marco, additional

Published
2022
Full Text
View/download PDF

20. Clopidogrel Monotherapy After 1-Month Dual Antiplatelet Therapy in Percutaneous Coronary Intervention: From the STOPDAPT-2 Total Cohort

Author

Obayashi, Yuki, Watanabe, Hirotoshi, Morimoto, Takeshi, Yamamoto, Ko, Natsuaki, Masahiro, Domei, Takenori, Yamaji, Kyohei, Suwa, Satoru, Isawa, Tsuyoshi, Watanabe, Hiroki, Yoshida, Ruka, Sakamoto, Hiroki, Akao, Masaharu, Hata, Yoshiki, Morishima, Itsuro, Tokuyama, Hideo, Yagi, Masahiro, Suzuki, Hiroshi, Wakabayashi, Kohei, Suematsu, Nobuhiro, Inada, Tsukasa, Tamura, Toshihiro, Okayama, Hideki, Abe, Mitsuru, Kawai, Kazuya, Nakao, Koichi, Ando, Kenji, Tanabe, Kengo, Ikari, Yuji, Morino, Yoshihiro, Kadota, Kazushige, Furukawa, Yutaka, Nakagawa, Yoshihisa, and Kimura, Takeshi

Subjects
chronic coronary syndrome, Clinical Trials as Topic, Aspirin, percutaneous coronary intervention, Myocardial Infarction, Hemorrhage, antiplatelet therapy, Clopidogrel, acute coronary syndrome, coronary stent, Treatment Outcome, Humans, Cardiology and Cardiovascular Medicine, Platelet Aggregation Inhibitors
Abstract

Background: The benefit of clopidogrel monotherapy after 1-month dual antiplatelet therapy (DAPT) compared with 12-month DAPT with aspirin and clopidogrel was demonstrated in the STOPDAPT-2 (Short and Optimal Duration of Dual Antiplatelet Therapy After Everolimus-Eluting Cobalt-Chromium Stent-2), but not in the STOPDAPT-2 acute coronary syndrome (ACS); however, both trials were underpowered based on the actual event rates. Methods: We obtained the prespecified pooled population of 5997 patients as the STOPDAPT-2 total cohort (STOPDAPT-2: N=3009/STOPDAPT-2 ACS: N=2988; ACS: N=4136/chronic coronary syndrome [CCS]: N=1861), comprising 2993 patients assigned to 1-month DAPT followed by clopidogrel monotherapy, and 3004 patients assigned to 12-month DAPT with aspirin and clopidogrel after percutaneous coronary intervention. The primary end point was the composite of cardiovascular (cardiovascular death, myocardial infarction, definite stent thrombosis, or any stroke) or bleeding (Thrombolysis in Myocardial Infarction major/minor) end points at 1 year. Results: One-month DAPT was noninferior to 12-month DAPT for the primary end point (2.84% versus 3.04%; hazard ratio [HR], 0.94 [95% CI, 0.70–1.27]; P noninferiority =0.001; P superiority =0.68). There was no significant risk-difference for the cardiovascular end point between the 1- and 12-month DAPT groups (2.40% versus 1.97%; HR, 1.24 [95% CI, 0.88–1.75]; P noninferiority =0.14; P superiority =0.23). There was a lower risk of the bleeding end point with 1-month DAPT relative to 12-month DAPT (0.50% versus 1.31%; HR, 0.38 [95% CI, 0.21–0.70]; P superiority =0.002). One-month DAPT relative to 12-month DAPT was associated with a lower risk for major bleeding regardless of ACS or CCS (ACS: HR, 0.46 [95% CI, 0.23–0.94]; P =0.03, and CCS: HR, 0.26 [95% CI, 0.09–0.79]; P =0.02; P interaction =0.40), while it was associated with a numerical increase in cardiovascular events in ACS patients, but not in CCS patients, although not statistically significant and without interaction (ACS: HR, 1.50 [95% CI, 0.99–2.27]; P =0.053, and CCS: HR, 0.74 [95% CI, 0.38–1.45]; P =0.39; P interaction =0.08). Conclusions: Clopidogrel monotherapy after 1-month DAPT compared with 12-month DAPT with aspirin and clopidogrel had a benefit in reducing major bleeding events without being associated with increase in cardiovascular events. Registration: URL: https://www.clinicaltrials.gov ; Unique identifiers: NCT02619760, NCT03462498.

Published
2022

21. TCT-21 Preferred Strategy in the Era of Short-Term Dual Antiplatelet Therapy: A Systematic Review and Network Meta-analysis of Randomized Trials

Author

Kuno, Toshiki, primary, Shoji, Satoshi, additional, Ueyama, Hiroki, additional, Takagi, Hisato, additional, Briasoulis, Alexandros, additional, Kim, Hyo-Soo, additional, Koo, Bon-Kwon, additional, Kang, Jeehoon, additional, Watanabe, Hirotoshi, additional, Kimura, Takeshi, additional, and Kohsaka, Shun, additional

Published
2022
Full Text
View/download PDF

24. Dexmedetomidine versus haloperidol for sedation of non-intubated patients with hyperactive delirium during the night in a high dependency unit: study protocol for an open-label, parallel-group, randomized controlled trial (DEX-HD trial).

Author

Minami, Takuma, Watanabe, Hirotoshi, Kato, Takao, Ikeda, Kaori, Ueno, Kentaro, Matsuyama, Ai, Maeda, Junya, Sakai, Yoji, Harada, Hisako, Kuriyama, Akira, Yamaji, Kyohei, Kitajima, Naoki, Kamei, Jun, Takatani, Yudai, Sato, Yuki, Yamashita, Yugo, Mizota, Toshiyuki, and Ohtsuru, Shigeru

Subjects
*INTENSIVE care units, *DRUG efficacy, *EXPERIMENTAL design, *ANESTHESIA, *TIME, *TERTIARY care, *PATIENTS, *INVESTIGATIONAL drugs, *IMIDAZOLES, *HALOPERIDOL, *RANDOMIZED controlled trials, *TREATMENT effectiveness, *DELIRIUM, *EMERGENCY medical services, *RESEARCH funding, *PATIENT safety, *EVALUATION
Abstract

Background: Delirium is common in critically ill patients. Haloperidol has long been used for the treatment of delirium. Dexmedetomidine has recently been used to treat delirium among intubated critically ill patients. However, the efficacy of dexmedetomidine for delirium in non-intubated critically ill patients remains unknown. We hypothesize that dexmedetomidine is superior to haloperidol for sedation of patients with hyperactive delirium, and would reduce the prevalence of delirium among non-intubated patients after administration. We will conduct a randomized controlled trial to compare dexmedetomidine and haloperidol for the treatment of nocturnal hyperactive delirium in non-intubated patients in high dependency units (HDUs). Methods: This is an open-label, parallel-group, randomized controlled trial to compare the efficacy and safety of dexmedetomidine and haloperidol for nocturnal hyperactive delirium in non-intubated patients at two HDUs of a tertiary hospital. We will recruit consecutive non-intubated patients who are admitted to the HDU from the emergency room, and allocate them in a 1:1 ratio to the dexmedetomidine or haloperidol group in advance. The allocated investigational drug will be administered only when participants develop hyperactive delirium (Richmond Agitation-Sedation Scale [RASS] score ≥1 and a positive score on the Confusion Assessment Method for the ICU between 19:00 and 6:00 the next day) during the night at an HDU. Dexmedetomidine is administered continuously, while haloperidol is administered intermittently. The primary outcome is the proportion of participants who achieve the targeted sedation level (RASS score of between -3 and 0) 2h after the administration of the investigational drug. Secondary outcomes include the sedation level and prevalence of delirium on the day following the administration of the investigational drugs, and safety. We plan to enroll 100 participants who develop nocturnal hyperactive delirium and receive one of the two investigational drugs. Discussion: This is the first randomized controlled trial to compare the efficacy and safety of dexmedetomidine and haloperidol for sedation of non-intubated critically ill patients with hyperactive delirium in HDUs. The results of this study may confirm whether dexmedetomidine could be another option to sedate patients with hyperactive delirium. Trial registration: Japan Registry of Clinical Trials, jRCT1051220015, registered on 21 April 2022. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

25. Rationale, Design, and Baseline Characteristics of the CURRENT AS Registry-2

Author

Takeji, Yasuaki, Taniguchi, Tomohiko, Morimoto, Takeshi, Shirai, Shinichi, Kitai, Takeshi, Tabata, Hiroyuki, Kitano, Kazuki, Ono, Nobuhisa, Murai, Ryosuke, Osakada, Kohei, Murata, Koichiro, Nakai, Masanao, Tsuneyoshi, Hiroshi, Tada, Tomohisa, Amano, Masashi, Shiomi, Hiroki, Watanabe, Hirotoshi, Yoshikawa, Yusuke, Yamamoto, Ko, Toyofuku, Mamoru, Tatsushima, Shojiro, Kanamori, Norino, Miyake, Makoto, Nakayama, Hiroyuki, Nagao, Kazuya, Izuhara, Masayasu, Nakatsuma, Kenji, Inoko, Moriaki, Fujita, Takanari, Kimura, Masahiro, Ishii, Mitsuru, Usami, Shunsuke, Sawada, Kenichiro, Nakazeki, Fumiko, Okabayashi, Marie, Shirotani, Manabu, Inuzuka, Yasutaka, Komiya, Tatsuhiko, Minatoya, Kenji, and Kimura, Takeshi

Subjects
Aged, 80 and over, Heart Valve Prosthesis Implantation, Male, Transcatheter aortic valve implantation, Aortic stenosis, Surgical aortic valve replacement, Aortic Valve Stenosis, Severity of Illness Index, Transcatheter Aortic Valve Replacement, Treatment Outcome, Risk Factors, Aortic Valve, Natriuretic Peptide, Brain, Humans, Female, Prospective Studies, Registries
Abstract

BACKGROUND: There is scarce data evaluating the current practice pattern and clinical outcomes for patients with severe aortic stenosis (AS), including both those who underwent surgical aortic valve replacement (SAVR) or transcatheter aortic valve implantation (TAVI) and those who were managed conservatively in the TAVI era.Methods and Results: The Contemporary outcomes after sURgery and medical tREatmeNT in patients with severe Aortic Stenosis (CURRENT AS) Registry-2 is a prospective, physician-initiated, multicenter registry enrolling consecutive patients who were diagnosed with severe AS between April 2018 and December 2020 among 21 centers in Japan. The rationale for the prospective enrollment was to standardize the assessment of symptomatic status, echocardiographic evaluation, and other recommended diagnostic examinations such as computed tomography and measurement of B-type natriuretic peptide. Moreover, the schedule of clinical and echocardiographic follow up was prospectively defined and strongly recommended for patients who were managed conservatively. The entire study population consisted of 3, 394 patients (mean age: 81.6 years and women: 60%). Etiology of AS was degenerative in 90% of patients. AS-related symptoms were present in 60% of patients; these were most often heart failure symptoms. The prevalence of high- and low-gradient AS was 58% and 42%, respectively, with classical and paradoxical low-flow low-gradient AS in 4.5% and 6.7%, respectively. CONCLUSIONS: The CURRENT AS Registry-2 might be large and meticulous enough to determine the appropriate timing of intervention for patients with severe AS in contemporary clinical practice.

Published
2022

26. Comparison of Clopidogrel Monotherapy After 1 to 2 Months of Dual Antiplatelet Therapy With 12 Months of Dual Antiplatelet Therapy in Patients With Acute Coronary Syndrome: The STOPDAPT-2 ACS Randomized Clinical Trial

Author

Watanabe, Hirotoshi, Morimoto, Takeshi, Natsuaki, Masahiro, Yamamoto, Ko, Obayashi, Yuki, Ogita, Manabu, Suwa, Satoru, Isawa, Tsuyoshi, Domei, Takenori, Yamaji, Kyohei, Tatsushima, Shojiro, Watanabe, Hiroki, Ohya, Masanobu, Tokuyama, Hideo, Tada, Tomohisa, Sakamoto, Hiroki, Mori, Hiroyoshi, Suzuki, Hiroshi, Nishikura, Tenjin, Wakabayashi, Kohei, Hibi, Kiyoshi, Abe, Mitsuru, Kawai, Kazuya, Nakao, Koichi, Ando, Kenji, Tanabe, Kengo, Ikari, Yuji, Morino, Yoshihiro, Kadota, Kazushige, Furukawa, Yutaka, Nakagawa, Yoshihisa, and Kimura, Takeshi

Subjects
Male, Myocardial Infarction, Drug-Eluting Stents, Hemorrhage, Clopidogrel, Percutaneous Coronary Intervention, Humans, Drug Therapy, Combination, Female, Acute Coronary Syndrome, Cardiology and Cardiovascular Medicine, Platelet Aggregation Inhibitors, Original Investigation, Aged
Abstract

IMPORTANCE: Clopidogrel monotherapy after short dual antiplatelet therapy (DAPT) after percutaneous coronary intervention (PCI) has not yet been fully investigated in patients with acute coronary syndrome (ACS). OBJECTIVE: To test the hypothesis of noninferiority of 1 to 2 months of DAPT compared with 12 months of DAPT for a composite end point of cardiovascular and bleeding events in patients with ACS. DESIGN, SETTING, AND PARTICIPANTS: This multicenter, open-label, randomized clinical trial enrolled 4169 patients with ACS who underwent successful PCI using cobalt-chromium everolimus-eluting stents at 96 centers in Japan from December 2015 through June 2020. These data were analyzed from June to July 2021. INTERVENTIONS: Patients were randomized either to 1 to 2 months of DAPT followed by clopidogrel monotherapy (n = 2078) or to 12 months of DAPT with aspirin and clopidogrel (n = 2091). MAIN OUTCOMES AND MEASURES: The primary end point was a composite of cardiovascular (cardiovascular death, myocardial infarction [MI], any stroke, or definite stent thrombosis) or bleeding (Thrombolysis in MI major or minor bleeding) events at 12 months, with a noninferiority margin of 50% on the hazard ratio (HR) scale. The major secondary end points were cardiovascular and bleeding components of the primary end point. RESULTS: Among 4169 randomized patients, 33 withdrew consent. Of the 4136 included patients, the mean (SD) age was 66.8 (11.9) years, and 856 (21%) were women, 2324 (56%) had ST-segment elevation MI, and 826 (20%) had non–ST-segment elevation MI. A total of 4107 patients (99.3%) completed the 1-year follow-up in June 2021. One to 2 months of DAPT was not noninferior to 12 months of DAPT for the primary end point, which occurred in 65 of 2058 patients (3.2%) in the 1- to 2-month DAPT group and in 58 of 2057 patients (2.8%) in the 12-month DAPT group (absolute difference, 0.37% [95% CI, −0.68% to 1.42%]; HR, 1.14 [95% CI, 0.80-1.62]; P for noninferiority = .06). The major secondary cardiovascular end point occurred in 56 patients (2.8%) in the 1- to 2-month DAPT group and in 38 patients (1.9%) in the 12-month DAPT group (absolute difference, 0.90% [95% CI, −0.02% to 1.82%]; HR, 1.50 [95% CI, 0.99-2.26]). The major secondary bleeding end point occurred in 11 patients (0.5%) in the 1- to 2-month DAPT group and 24 patients (1.2%) in the 12-month DAPT group (absolute difference, −0.63% [95% CI, −1.20% to −0.06%]; HR, 0.46 [95% CI, 0.23-0.94]). CONCLUSIONS AND RELEVANCE: In patients with ACS with successful PCI, clopidogrel monotherapy after 1 to 2 months of DAPT failed to attest noninferiority to standard 12 months of DAPT for the net clinical benefit with a numerical increase in cardiovascular events despite reduction in bleeding events. The directionally different efficacy and safety outcomes indicate the need for further clinical trials. TRIAL REGISTRATION: ClinicalTrials.gov Identifiers: NCT02619760 and NCT03462498

Published
2022

27. Dual antiplatelet therapy duration after percutaneous coronary intervention in high bleeding risk: a meta-analysis of randomized trials.

Author

Costa, Francesco, Montalto, Claudio, Branca, Mattia, Hong, Sung-Jin, Watanabe, Hirotoshi, Franzone, Anna, Vranckx, Pascal, Hahn, Joo-Yong, Gwon, Hyeon-Cheol, Feres, Fausto, Jang, Yangsoo, Luca, Giuseppe De, Kedhi, Elvin, Cao, Davide, Steg, Philippe Gabriel, Bhatt, Deepak L, Stone, Gregg W, Micari, Antonio, Windecker, Stephan, and Kimura, Takeshi

Subjects
PERCUTANEOUS coronary intervention, PLATELET aggregation inhibitors, TREATMENT duration, MAJOR adverse cardiovascular events, MYOCARDIAL infarction, HEMORRHAGE
Abstract

Aims The optimal duration of dual antiplatelet therapy (DAPT) after percutaneous coronary intervention (PCI) in patients at high bleeding risk (HBR) is still debated. The current study, using the totality of existing evidence, evaluated the impact of an abbreviated DAPT regimen in HBR patients. Methods and results A systematic review and meta-analysis was performed to search randomized clinical trials comparing abbreviated [i.e. very-short (1 month) or short (3 months)] with standard (≥6 months) DAPT in HBR patients without indication for oral anticoagulation. A total of 11 trials, including 9006 HBR patients, were included. Abbreviated DAPT reduced major or clinically relevant non-major bleeding [risk ratio (RR): 0.76, 95% confidence interval (CI): 0.61–0.94; I 2 = 28%], major bleeding (RR: 0.80, 95% CI: 0.64–0.99, I 2 = 0%), and cardiovascular mortality (RR: 0.79, 95% CI: 0.65–0.95, I 2 = 0%) compared with standard DAPT. No difference in all-cause mortality, major adverse cardiovascular events, myocardial infarction, or stent thrombosis was observed. Results were consistent, irrespective of HBR definition and clinical presentation. Conclusion In HBR patients undergoing PCI, a 1- or 3-month abbreviated DAPT regimen was associated with lower bleeding and cardiovascular mortality, without increasing ischaemic events, compared with a ≥6-month DAPT regimen. Study registration PROSPERO registration number CRD42021284004 [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

28. Changes in demographics, clinical practices and long-term outcomes of patients with ST segment-elevation myocardial infarction who underwent coronary revascularisation in the past two decades: cohort study

Author

Takeji, Yasuaki, primary, Shiomi, Hiroki, additional, Morimoto, Takeshi, additional, Yoshikawa, Yusuke, additional, Taniguchi, Ryoji, additional, Mutsumura-Nakano, Yukiko, additional, Yamamoto, Ko, additional, Yamaji, Kyohei, additional, Tazaki, Junichi, additional, Kato, Eri Toda, additional, Watanabe, Hirotoshi, additional, Yamamoto, Erika, additional, Yamashita, Yugo, additional, Fuki, Masayuki, additional, Suwa, Satoru, additional, Inoko, Moriaki, additional, Takeda, Teruki, additional, Shirotani, Manabu, additional, Ehara, Natsuhiko, additional, Ishii, Katsuhisa, additional, Inada, Tsukasa, additional, Tamura, Toshihiro, additional, Onodera, Tomoya, additional, Shinoda, Eiji, additional, Yamamoto, Takashi, additional, Watanabe, Hiroki, additional, Yaku, Hidenori, additional, Nakatsuma, Kenji, additional, Sakamoto, Hiroki, additional, Ando, Kenji, additional, Soga, Yoshiharu, additional, Furukawa, Yutaka, additional, Sato, Yukihito, additional, Nakagawa, Yoshihisa, additional, Kadota, Kazushige, additional, Komiya, Tatsuhiko, additional, Minatoya, Kenji, additional, and Kimura, Takeshi, additional

Published
2021
Full Text
View/download PDF

29. Overview of the 84th Annual Scientific Meeting of the Japanese Circulation Society ― Change Practice! ―

Author

Ono, Koh, primary, Shizuta, Satoshi, additional, Yamamoto, Erika, additional, Saito, Naritatsu, additional, Ozasa, Neiko, additional, Kato, Takao, additional, Kato, Eri, additional, Horie, Takahiro, additional, Tazaki, Junichi, additional, Shiomi, Hiroki, additional, Watanabe, Shin, additional, Watanabe, Hirotoshi, additional, Yamashita, Yugo, additional, Yoshikawa, Yusuke, additional, Kinoshita, Hideyuki, additional, Makiyama, Takeru, additional, Yoshida, Yoshinori, additional, Ashida, Noboru, additional, Nakagawa, Yasuaki, additional, Nakashima, Yasuhiro, additional, Baba, Osamu, additional, Kohjitani, Hirohiko, additional, Kimura, Masahiro, additional, Inazumi, Hideaki, additional, Yoshizawa, Takashi, additional, Komasa, Akihiro, additional, and Kimura, Takeshi, additional

Published
2021
Full Text
View/download PDF

31. Ischemic and Bleeding Risk After Percutaneous Coronary Intervention in Patients With Prior Ischemic and Hemorrhagic Stroke

Author

Natsuaki, Masahiro, Morimoto, Takeshi, Watanabe, Hirotoshi, Nakagawa, Yoshihisa, Furukawa, Yutaka, Kadota, Kazushige, Akasaka, Takashi, Hanaoka, Igarashi, Keiichi, Kozuma, Ken, Tanabe, Kengo, Morino, Yoshihiro, Muramatsu, Toshiya, and Kimura, Takeshi

Subjects
percutaneous coronary intervention, cardiovascular diseases, stroke, coronary artery disease
Abstract

Background: Prior stroke is regarded as risk factor for bleeding after percutaneous coronary intervention (PCI). However, there is a paucity of data on detailed bleeding risk of patients with prior hemorrhagic and ischemic strokes after PCI. Methods and Results: In a pooled cohort of 19475 patients from 3 Japanese PCI studies, we assessed the influence of prior hemorrhagic (n=285) or ischemic stroke (n=1773) relative to no-prior stroke (n=17417) on ischemic and bleeding outcomes after PCI. Cumulative 3-year incidences of the co-primary bleeding end points of intracranial hemorrhage, non-intracranial global utilization of streptokinase and tissue plasminogen activator for occluded coronary arteries (GUSTO) moderate/severe bleeding, and the primary ischemic end point of ischemic stroke/myocardial infarction were higher in the prior hemorrhagic and ischemic stroke groups than in the no-prior stroke group (6.8%, 2.5%, and 1.3%, P

Published
2019

34. Prognostic Impact of Aortic Valve Area in Conservatively Managed Patients With Asymptomatic Severe Aortic Stenosis With Preserved Ejection Fraction

Author

Kanamori, Norio, primary, Taniguchi, Tomohiko, additional, Morimoto, Takeshi, additional, Watanabe, Hirotoshi, additional, Shiomi, Hiroki, additional, Ando, Kenji, additional, Murata, Koichiro, additional, Kitai, Takeshi, additional, Kawase, Yuichi, additional, Izumi, Chisato, additional, Miyake, Makoto, additional, Mitsuoka, Hirokazu, additional, Kato, Masashi, additional, Hirano, Yutaka, additional, Matsuda, Shintaro, additional, Nagao, Kazuya, additional, Inada, Tsukasa, additional, Mabuchi, Hiroshi, additional, Takeuchi, Yasuyo, additional, Yamane, Keiichiro, additional, Toyofuku, Mamoru, additional, Ishii, Mitsuru, additional, Minamino‐Muta, Eri, additional, Kato, Takao, additional, Inoko, Moriaki, additional, Ikeda, Tomoyuki, additional, Komasa, Akihiro, additional, Ishii, Katsuhisa, additional, Hotta, Kozo, additional, Higashitani, Nobuya, additional, Kato, Yoshihiro, additional, Inuzuka, Yasutaka, additional, Maeda, Chiyo, additional, Jinnai, Toshikazu, additional, Morikami, Yuko, additional, Saito, Naritatsu, additional, Minatoya, Kenji, additional, Aoyama, Takeshi, additional, Kimura, Takeshi, additional, Sakata, Ryuzo, additional, Imai, Masao, additional, Tazaki, Junichi, additional, Toyota, Toshiaki, additional, Higami, Hirooki, additional, Kawaji, Tetsuma, additional, Shirai, Shinichi, additional, Korai, Kengo, additional, Arita, Takeshi, additional, Miura, Shiro, additional, Yamaji, Kyohei, additional, Kim, Kitae, additional, Iwasaki, Keiichiro, additional, Miyawaki, Hiroshi, additional, Misao, Ayumi, additional, Kuwayama, Akimune, additional, Ohya, Masanobu, additional, Shimada, Takenobu, additional, Amano, Hidewo, additional, Amano, Masashi, additional, Takahashi, Yusuke, additional, Yoshikawa, Yusuke, additional, Nishimura, Shunsuke, additional, Kuroda, Maiko, additional, Mizoguchi, Tetsu, additional, Yokomatsu, Takafumi, additional, Kushiyama, Akihiro, additional, Yaku, Hidenori, additional, Watanabe, Toshimitsu, additional, Sugioka, Sachiko, additional, Takahashi, Naoki, additional, Fukuchi, Kohei, additional, Takeda, Teruki, additional, Sakaguchi, Tomoko, additional, Maeda, Keiko, additional, Yamaji, Masayuki, additional, Maenaka, Motoyoshi, additional, Tadano, Yutaka, additional, Motooka, Makoto, additional, Nishikawa, Ryusuke, additional, Kawato, Mitsunori, additional, Kinoshita, Minako, additional, Aida, Kenji, additional, Takahashi, Kousuke, additional, Ko, Euihong, additional, Masunaga, Nobutoyo, additional, Ogawa, Hisashi, additional, Iguchi, Moritake, additional, Unoki, Takashi, additional, Takabayashi, Kensuke, additional, Hamatani, Yasuhiro, additional, Yamashita, Yugo, additional, Tsuji, Shuhei, additional, Nishio, Soji, additional, Seki, Jyunya, additional, Yamada, Miho, additional, Kawamoto, Akira, additional, Sogabe, Kouji, additional, Tachiiri, Michiya, additional, Matsumura, Yukiko, additional, Ota, Chihiro, additional, Minakata, Kenji, additional, Hanyu, Michiya, additional, Yamazaki, Fumio, additional, Koyama, Tadaaki, additional, Komiya, Tatsuhiko, additional, Yamanaka, Kazuo, additional, Nishiwaki, Noboru, additional, Nakajima, Hiroyuki, additional, Ohnaka, Motoaki, additional, Osada, Hiroaki, additional, Meshii, Katsuaki, additional, Saga, Toshihiko, additional, Onoe, Masahiko, additional, Kitayama, Hitoshi, additional, Nakayama, Shogo, additional, Sakaguchi, Genichi, additional, Iwakura, Atsushi, additional, Shiraga, Kotaro, additional, Ueyama, Koji, additional, Fujiwara, Keiichi, additional, Fukumoto, Atsushi, additional, Miwa, Senri, additional, Nishizawa, Junichiro, additional, Kitano, Mitsuru, additional, Nakatsuma, Kenji, additional, and Sasa, Tomoki, additional

Published
2019
Full Text
View/download PDF

35. One-year clinical outcomes of patients with versus without acute coronary syndrome with 3-month duration of dual antiplatelet therapy after everolimus-eluting stent implantation.

Author

Natsuaki, Masahiro, Morimoto, Takeshi, Yamamoto, Erika, Watanabe, Hirotoshi, Furukawa, Yutaka, Abe, Mitsuru, Nakao, Koichi, Ishikawa, Tetsuya, Kawai, Kazuya, Yunoki, Kei, Shimizu, Shogo, Akao, Masaharu, Miki, Shinji, Yamamoto, Masashi, Okada, Hisayuki, Hoshino, Kozo, Kadota, Kazushige, Morino, Yoshihiro, Hanaoka, Keiichi Igarashi, and Tanabe, Kengo

Subjects
DRUG-eluting stents, ACUTE coronary syndrome, ANGINA pectoris, CORONARY disease, MYOCARDIAL infarction
Abstract

There has been no previous prospective study evaluating 3-month dual antiplatelet therapy (DAPT) after cobalt-chromium everolimus-eluting stent (CoCr-EES) implantation in patients with acute coronary syndrome (ACS). The STOPDAPT trial is a prospective multi-center single-arm study evaluating 3-month DAPT duration in all-comer population after CoCr-EES implantation. Among 1525 study patients enrolled from 58 Japanese centers, the present study compared the 1-year clinical outcomes between ACS patients (N = 487) and stable coronary artery disease (CAD) patients (N = 1038). In the ACS group, 228 patients (47%) had unstable angina and 259 patients (53%) had myocardial infarction. The primary endpoint was a composite of cardiovascular death, myocardial infarction, stroke, definite stent thrombosis (ST) and TIMI major/minor bleeding. Thienopyridine was discontinued within 4-month in 455 patients (94.0%) in the ACS group and 977 patients (94.3%) in the stable CAD group. Cumulative 1-year incidence of and the adjusted risk for the primary endpoint were not significantly different between the ACS and stable CAD groups (2.3% vs. 3.0%, P = 0.42, and HR 0.94, 95%CI 0.44–1.87, P = 0.87). In the 3-month landmark analysis, cumulative incidence of the primary endpoint was also not significantly different between the ACS and stable CAD groups (1.3% vs. 2.4%, P = 0.16). There was no definite/probable ST through 1-year in both groups. In the propensity matched analysis, the cumulative 1-year incidence of the primary endpoint were similar between the ACS and stable CAD groups (2.3% versus 2.1%, P = 0.82). In conclusion, stopping DAPT at 3 months after CoCr-EES implantation in patients with ACS including 47% of unstable angina was as safe as that in patients with stable CAD. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

36. Ischemic and Bleeding Risk After Percutaneous Coronary Intervention in Patients With Prior Ischemic and Hemorrhagic Stroke.

Author

Masahiro Natsuaki, Takeshi Morimoto, Hirotoshi Watanabe, Yoshihisa Nakagawa, Yutaka Furukawa, Kazushige Kadota, Takashi Akasaka, Keiichi Igarashi Hanaoka, Ken Kozuma, Kengo Tanabe, Yoshihiro Morino, Toshiya Muramatsu, Takeshi Kimura, Natsuaki, Masahiro, Morimoto, Takeshi, Watanabe, Hirotoshi, Nakagawa, Yoshihisa, Furukawa, Yutaka, Kadota, Kazushige, and Akasaka, Takashi

Published
2019
Full Text
View/download PDF

37. Prognostic Impact of Baseline Hemoglobin Levels on Long-Term Thrombotic and Bleeding Events After Percutaneous Coronary Interventions.

Author

Kazuya Nagao, Hirotoshi Watanabe, Takeshi Morimoto, Tsukasa Inada, Fujio Hayashi, Yoshihisa Nakagawa, Yutaka Furukawa, Kazushige Kadota, Takashi Akasaka, Masahiro Natsuaki, Ken Kozuma, Kengo Tanabe, Yoshihiro Morino, Hiroki Shiomi, Takeshi Kimura, Nagao, Kazuya, Watanabe, Hirotoshi, Morimoto, Takeshi, Inada, Tsukasa, and Hayashi, Fujio

Published
2019
Full Text
View/download PDF

39. Sex Differences in Long-Term Clinical Outcomes in Patients With Atrial Fibrillation Undergoing Coronary Stent Implantation

Author

Matsumura-Nakano, Yukiko, primary, Shiomi, Hiroki, additional, Morimoto, Takeshi, additional, Shizuta, Satoshi, additional, Yamaji, Kyohei, additional, Watanabe, Hirotoshi, additional, Yoshikawa, Yusuke, additional, Taniguchi, Tomohiko, additional, Kawaji, Tetsuma, additional, Natsuaki, Masahiro, additional, Akasaka, Takashi, additional, Hanaoka, Keiichi, additional, Kadota, Kazushige, additional, Kozuma, Ken, additional, Tanabe, Kengo, additional, Nakagawa, Yoshihisa, additional, Muramatsu, Toshiya, additional, Morino, Yoshihiro, additional, Ando, Kenji, additional, and Kimura, Takeshi, additional

Published
2018
Full Text
View/download PDF

40. Prognostic Impact of Left Ventricular Ejection Fraction in Patients With Severe Aortic Stenosis

Author

Taniguchi, Tomohiko, primary, Morimoto, Takeshi, additional, Shiomi, Hiroki, additional, Ando, Kenji, additional, Kanamori, Norio, additional, Murata, Koichiro, additional, Kitai, Takeshi, additional, Kadota, Kazushige, additional, Izumi, Chisato, additional, Nakatsuma, Kenji, additional, Sasa, Tomoki, additional, Watanabe, Hirotoshi, additional, Kuwabara, Yasuhide, additional, Makiyama, Takeru, additional, Ono, Koh, additional, Shizuta, Satoshi, additional, Kato, Takao, additional, Saito, Naritatsu, additional, Minatoya, Kenji, additional, Kimura, Takeshi, additional, Taniguchi, Tomohiko, additional, Imai, Masao, additional, Tazaki, Junichi, additional, Toyota, Toshiaki, additional, Higami, Hirooki, additional, Kawaji, Tetsuma, additional, Shirai, Shinichi, additional, Kourai, Kengo, additional, Arita, Takeshi, additional, Miura, Shiro, additional, Yamaji, Kyohei, additional, Aoyama, Takeshi, additional, Onodera, Tomoya, additional, Furukawa, Yutaka, additional, Kim, Kitae, additional, Kawase, Yuichi, additional, Iwasaki, Keiichiro, additional, Miyawaki, Hiroshi, additional, Misao, Ayumi, additional, Kuwayama, Akimune, additional, Ohya, Masanobu, additional, Shimada, Takenobu, additional, Amano, Hidewo, additional, Nakagawa, Yoshihisa, additional, Miyake, Makoto, additional, Amano, Masashi, additional, Takahashi, Yusuke, additional, Yoshikawa, Yusuke, additional, Nishimura, Shunsuke, additional, Kuroda, Maiko, additional, Shirotani, Manabu, additional, Mitsuoka, Hirokazu, additional, Miki, Shinji, additional, Mizoguchi, Tetsu, additional, Kato, Masashi, additional, Yokomatsu, Takafumi, additional, Kushiyama, Akihiro, additional, Yaku, Hidenori, additional, Watanabe, Toshimitsu, additional, Miyazaki, Shunichi, additional, Hirano, Yutaka, additional, Matsuda, Mitsuo, additional, Matsuda, Shintaro, additional, Sugioka, Sachiko, additional, Inada, Tsukasa, additional, Nagao, Kazuya, additional, Takahashi, Naoki, additional, Fukuchi, Kohei, additional, Murakami, Tomoyuki, additional, Mabuchi, Hiroshi, additional, Takeda, Teruki, additional, Sakaguchi, Tomoko, additional, Maeda, Keiko, additional, Yamaji, Masayuki, additional, Maenaka, Motoyoshi, additional, Tadano, Yutaka, additional, Sakamoto, Hiroki, additional, Takeuchi, Yasuyo, additional, Motooka, Makoto, additional, Nishikawa, Ryusuke, additional, Eizawa, Hiroshi, additional, Yamane, Keiichiro, additional, Kawato, Mitsunori, additional, Kinoshita, Minako, additional, Aida, Kenji, additional, Tamura, Takashi, additional, Toyofuku, Mamoru, additional, Takahashi, Kousuke, additional, Ko, Euihong, additional, Akao, Masaharu, additional, Ishii, Mitsuru, additional, Masunaga, Nobutoyo, additional, Ogawa, Hisashi, additional, Iguchi, Moritake, additional, Unoki, Takashi, additional, Takabayashi, Kensuke, additional, Hamatani, Yasuhiro, additional, Yamashita, Yugo, additional, Inoko, Moriaki, additional, Minamino-Muta, Eri, additional, Himura, Yoshihiro, additional, Ikeda, Tomoyuki, additional, Ishii, Katsuhisa, additional, Komasa, Akihiro, additional, Sato, Yukihito, additional, Hotta, Kozo, additional, Tsuji, Shuhei, additional, Hiraoka, Yuji, additional, Higashitani, Nobuya, additional, Kouchi, Ichiro, additional, Kato, Yoshihiro, additional, Ikeguchi, Shigeru, additional, Inuzuka, Yasutaka, additional, Nishio, Soji, additional, Seki, Jyunya, additional, Shinoda, Eiji, additional, Yamada, Miho, additional, Kawamoto, Akira, additional, Maeda, Chiyo, additional, Konishi, Takashi, additional, Jinnai, Toshikazu, additional, Sogabe, Kouji, additional, Tachiiri, Michiya, additional, Matsumura, Yukiko, additional, Ota, Chihiro, additional, Kitaguchi, Shoji, additional, Morikami, Yuko, additional, Sakata, Ryuzo, additional, Minakata, Kenji, additional, Hanyu, Michiya, additional, Yamazaki, Fumio, additional, Koyama, Tadaaki, additional, Komiya, Tatsuhiko, additional, Yamanaka, Kazuo, additional, Nishiwaki, Noboru, additional, Nakajima, Hiroyuki, additional, Ohnaka, Motoaki, additional, Osada, Hiroaki, additional, Meshii, Katsuaki, additional, Saga, Toshihiko, additional, Onoe, Masahiko, additional, Nakayama, Shogo, additional, Sakaguchi, Genichi, additional, Iwakura, Atsushi, additional, Shiraga, Kotaro, additional, Ueyama, Koji, additional, Fujiwara, Keiichi, additional, Fukumoto, Atsushi, additional, Park, Masaki, additional, Nishizawa, Junichiro, additional, and Kitano, Mitsuru, additional

Published
2018
Full Text
View/download PDF

42. Prognostic Impact of Peak Aortic Jet Velocity in Conservatively Managed Patients With Severe Aortic Stenosis: An Observation From the CURRENT AS Registry

Author

Nakatsuma, Kenji, primary, Taniguchi, Tomohiko, additional, Morimoto, Takeshi, additional, Shiomi, Hiroki, additional, Ando, Kenji, additional, Kanamori, Norio, additional, Murata, Koichiro, additional, Kitai, Takeshi, additional, Kawase, Yuichi, additional, Izumi, Chisato, additional, Miyake, Makoto, additional, Mitsuoka, Hirokazu, additional, Kato, Masashi, additional, Hirano, Yutaka, additional, Matsuda, Shintaro, additional, Inada, Tsukasa, additional, Nagao, Kazuya, additional, Murakami, Tomoyuki, additional, Takeuchi, Yasuyo, additional, Yamane, Keiichiro, additional, Toyofuku, Mamoru, additional, Ishii, Mitsuru, additional, Minamino‐Muta, Eri, additional, Kato, Takao, additional, Inoko, Moriaki, additional, Ikeda, Tomoyuki, additional, Komasa, Akihiro, additional, Ishii, Katsuhisa, additional, Hotta, Kozo, additional, Higashitani, Nobuya, additional, Kato, Yoshihiro, additional, Inuzuka, Yasutaka, additional, Maeda, Chiyo, additional, Jinnai, Toshikazu, additional, Morikami, Yuko, additional, Saito, Naritatsu, additional, Minatoya, Kenji, additional, Kimura, Takeshi, additional, Imai, Masao, additional, Tazaki, Junichi, additional, Toyota, Toshiaki, additional, Higami, Hirooki, additional, Kawaji, Tetsuma, additional, Shirai, Shinichi, additional, Korai, Kengo, additional, Arita, Takeshi, additional, Miura, Shiro, additional, Yamaji, Kyohei, additional, Kim, Kitae, additional, Iwasaki, Keiichiro, additional, Miyawaki, Hiroshi, additional, Misao, Ayumi, additional, Kuwayama, Akimune, additional, Ohya, Masanobu, additional, Shimada, Takenobu, additional, Amano, Hidewo, additional, Amano, Masashi, additional, Takahashi, Yusuke, additional, Yoshikawa, Yusuke, additional, Nishimura, Shunsuke, additional, Kuroda, Maiko, additional, Mizoguchi, Tetsu, additional, Yokomatsu, Takafumi, additional, Kushiyama, Akihiro, additional, Yaku, Hidenori, additional, Watanabe, Toshimitsu, additional, Sugioka, Sachiko, additional, Takahashi, Naoki, additional, Fukuchi, Kohei, additional, Mabuchi, Hiroshi, additional, Takeda, Teruki, additional, Sakaguchi, Tomoko, additional, Yamaji, Masayuki, additional, Maenaka, Motoyoshi, additional, Tadano, Yutaka, additional, Motooka, Makoto, additional, Nishikawa, Ryusuke, additional, Kawato, Mitsunori, additional, Kinoshita, Minako, additional, Aida, Kenji, additional, Takahashi, Kousuke, additional, Ko, Euihong, additional, Masunaga, Nobutoyo, additional, Ogawa, Hisashi, additional, Iguchi, Moritake, additional, Unoki, Takashi, additional, Takabayashi, Kensuke, additional, Hamatani, Yasuhiro, additional, Yamashita, Yugo, additional, Tsuji, Shuhei, additional, Nishio, Soji, additional, Seki, Jyunya, additional, Yamada, Miho, additional, Kawamoto, Akira, additional, Sogabe, Kouji, additional, Tachiiri, Michiya, additional, Matsumura, Yukiko, additional, Ota, Chihiro, additional, Sakata, Ryuzo, additional, Minakata, Kenji, additional, Hanyu, Michiya, additional, Yamazaki, Fumio, additional, Koyama, Tadaaki, additional, Komiya, Tatsuhiko, additional, Yamanaka, Kazuo, additional, Nishiwaki, Noboru, additional, Ohnaka, Motoaki, additional, Osada, Hiroaki, additional, Meshii, Katsuaki, additional, Saga, Toshihiko, additional, Kitayama, Hitoshi, additional, Nakayama, Shogo, additional, Sakaguchi, Genichi, additional, Iwakura, Atsushi, additional, Shiraga, Kotaro, additional, Ueyama, Koji, additional, Fujiwara, Keiichi, additional, Fukumoto, Atsushi, additional, Miwa, Senri, additional, Nishizawa, Junichiro, additional, Kitano, Mitsuru, additional, Watanabe, Hirotoshi, additional, and Sasa, Tomoki, additional

Published
2017
Full Text
View/download PDF

43. APPLICATION OF DAPT SCORE TO PREDICT ISCHEMIC AND BLEEDING EVENTS IN JAPANESE PATIENTS UNDERGOING DRUG-ELUTING STENT IMPLANTATION: AN OBSERVATION FROM A POOLED COHORT OF THE CREDO-KYOTO COHORT-2, RESET, AND NEXT TRIALS

Author

Yoshikawa, Yusuke, primary, Shiomi, Hiroki, additional, Watanabe, Hirotoshi, additional, Natsuaki, Masahiro, additional, Kondo, Hirokazu, additional, Tamura, Toshihiro, additional, Morimoto, Takeshi, additional, Nakagawa, Yoshihisa, additional, and Kimura, Takeshi, additional

Published
2017
Full Text
View/download PDF

44. Transcatheter aortic valve implantation versus conservative management for severe aortic stenosis in real clinical practice.

Author

Takeji, Yasuaki, Taniguchi, Tomohiko, Morimoto, Takeshi, Saito, Naritatsu, Ando, Kenji, Shirai, Shinichi, Sakaguchi, Genichi, Arai, Yoshio, Fuku, Yasushi, Kawase, Yuichi, Komiya, Tatsuhiko, Ehara, Natsuhiko, Kitai, Takeshi, Koyama, Tadaaki, Watanabe, Shin, Watanabe, Hirotoshi, Shiomi, Hiroki, Minamino-Muta, Eri, Matsuda, Shintaro, and Yaku, Hidenori

Subjects
HEART valve prosthesis implantation, AORTIC stenosis, DIALYSIS catheters, MEDICAL registries, PROPENSITY score matching, INTRA-aortic balloon counterpulsation
Abstract

Background: Transcatheter aortic valve implantation (TAVI) is criticized by some as an expensive treatment in super-elder patients with limited life expectancy. However, there is a knowledge gap regarding the magnitude of clinical benefit provided by TAVI in comparison with conservative management in patients with severe aortic stenosis (AS) in real clinical practice, which would be important in the decision making for TAVI. Methods: We combined two independent registries, namely CURRENT AS and K-TAVI registries. CURRENT AS was a multicenter registry enrolling 3815 consecutive patients with severe AS irrespective to treatment modalities between January 2003 and December 2011. K-TAVI was a multicenter, prospective registry including 449 consecutive patients with severe AS, who underwent TAVI with SAPIEN XT balloon-expandable valves between October 2013 and June 2016. In these 2 registries, 449 patients received TAVI and 894 patients were managed with conservative strategy. We conducted propensity score matching and finally obtained a cohort of 556 patients (278 patients for each group) for the analysis. The primary outcome measures were all-cause death and heart failure (HF) hospitalization at 2-year. Results: The cumulative 2-year incidences of all-cause death and HF hospitalization were significantly lower in the TAVI group than in the conservative group (16.8% versus 36.6%, P<0.001, and 10.7% versus 37.2%, P<0.001). After adjusting the residual confounders, TAVI reduced the risks of all-cause death (HR, 0.46; 95%CI, 0.32–0.69; P = 0.0001) and HF hospitalizations (HR, 0.25; 95%CI, 0.16–0.40; P<0.0001) compared with conservative strategy. There was no difference in the cumulative incidence of non-cardiovascular death between the 2 groups. Conclusions: TAVI in the early Japanese experience was associated with striking risk reduction for all-cause death as well as HF hospitalization as compared with the historical cohort of patients with severe AS who were managed conservatively just before introduction of TAVI in Japan. [ABSTRACT FROM AUTHOR]

Published
2019
Full Text
View/download PDF

46. Effects of Age and Sex on Clinical Outcomes After Percutaneous Coronary Intervention Relative to Coronary Artery Bypass Grafting in Patients With Triple-Vessel Coronary Artery Disease

Author

Yamaji, Kyohei, primary, Shiomi, Hiroki, additional, Morimoto, Takeshi, additional, Nakatsuma, Kenji, additional, Toyota, Toshiaki, additional, Ono, Koh, additional, Furukawa, Yutaka, additional, Nakagawa, Yoshihisa, additional, Kadota, Kazushige, additional, Ando, Kenji, additional, Shirai, Shinichi, additional, Onodera, Tomoya, additional, Watanabe, Hirotoshi, additional, Natsuaki, Masahiro, additional, Sakata, Ryuzo, additional, Hanyu, Michiya, additional, Nishiwaki, Noboru, additional, Komiya, Tatsuhiko, additional, and Kimura, Takeshi, additional

Published
2016
Full Text
View/download PDF

47. Successful Management of Guidewire Kinking in a Patient With Subaortic Septal Bulging Using the Pull-Through Technique During Transapical Transcatheter Aortic Valve Implantation

Author

Toyota, Toshiaki, primary, Saito, Naritatsu, additional, Minakata, Kenji, additional, Imai, Masao, additional, Uehara, Kyokun, additional, Nishio, Hiroomi, additional, Kuroda, Yuki, additional, Watanabe, Hirotoshi, additional, Taniguchi, Tomohiko, additional, Tazaki, Junichi, additional, Yamazaki, Kazuhiro, additional, Daijo, Hiroki, additional, and Kimura, Takeshi, additional

Published
2016
Full Text
View/download PDF

48. Influence of Sex on Long-Term Outcomes After Implantation of Bare-Metal Stent

Author

Yamaji, Kyohei, primary, Shiomi, Hiroki, additional, Morimoto, Takeshi, additional, Toyota, Toshiaki, additional, Ono, Koh, additional, Furukawa, Yutaka, additional, Nakagawa, Yoshihisa, additional, Kadota, Kazushige, additional, Ando, Kenji, additional, Shirai, Shinichi, additional, Kato, Masayuki, additional, Takatsu, Yoshiki, additional, Doi, Osamu, additional, Kambara, Hirofumi, additional, Suwa, Satoru, additional, Onodera, Tomoya, additional, Watanabe, Hirotoshi, additional, Natsuaki, Masahiro, additional, and Kimura, Takeshi, additional

Published
2015
Full Text
View/download PDF

49. TCT-564 Clinical Predictors of Target Lesion Revascularization after SES or EES implantation

Author

Hiramori, Seiichi, primary, Watanabe, Hirotoshi, additional, Shiomi, Hiroki, additional, Kozuma, Ken, additional, Morimoto, Takeshi, additional, Igarashi, Keiichi, additional, Kadota, Kazushige, additional, Tanabe, Kengo, additional, Morino, Yoshihiro, additional, Shirai, Shinichi, additional, Ando, Kenji, additional, Nobuyoshi, Masakiyo, additional, and Kimura, Takeshi, additional

Published
2015
Full Text
View/download PDF

50. Successful balloon aortic valvuloplasty as a bridge therapy to transcatheter aortic valve implantation during the proctoring period

Author

Yanagisawa, Hiromu, primary, Saito, Naritatsu, additional, Imai, Masao, additional, Minakata, Kenji, additional, Fujita, Takanari, additional, Watanabe, Shin, additional, Watanabe, Hirotoshi, additional, Yamazaki, Kazuhiro, additional, Toyota, Toshiaki, additional, Taniguchi, Tomohiko, additional, Tazaki, Junichi, additional, Shizuta, Satoshi, additional, Daijo, Hiroki, additional, Sakata, Ryuzo, additional, and Kimura, Takeshi, additional

Published
2015
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results